Business Combinations (Narrative) (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended									12 Months Ended								1 Months Ended	3 Months Ended		12 Months Ended			12 Months Ended
	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010		Sep. 30, 2010	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2012 License Agreements [Member] Minimum [Member]	Jun. 30, 2012 License Agreements [Member] Maximum [Member]	Jun. 30, 2012 Customer Relationships [Member] Minimum [Member]	Jun. 30, 2012 Customer Relationships [Member] Maximum [Member]	Jun. 30, 2012 Trademarks [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member]	Jun. 30, 2012 Rising Pharmaceuticals Inc. [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member]	Jun. 30, 2011 Rising Pharmaceuticals Inc. [Member]	Jun. 30, 2010 Rising Pharmaceuticals Inc. [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member] Product Rights [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member] Product Rights [Member] Minimum [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member] Product Rights [Member] Maximum [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member] License Agreements [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member] Customer Relationships [Member]	Dec. 31, 2010 Rising Pharmaceuticals Inc. [Member] Trademarks [Member]
Business Acquisition [Line Items]
Business acquisition, purchase price																		$ 73,317		$ 73,317
Business acquisition, shares issued																		1,000
Business acquisition, value of shares issued																		9,000		9,000
Business acquisition, cash paid																		58,817		58,817
Business acquisition, liabilities assumed																		5,500		5,500
Business acquisition, deferred payment																		8,000		8,000
Business acquisition, additional consideration payable in one year																		1,500		1,500
Business acquisition, additional consideration payable in two years																		1,500		1,500
Business acquisition, additional consideration payable in three years																		1,500		1,500
Business acquisition, additional consideration payable in four years																		3,500		3,500
Business acquisition, EBITDA basis used to determine contingent consideration																		32,100
Business acquisition, maximum contingent consideration																		6,000		6,000
Business acquisition, accrued contingent consideration payable																			1,779
Business acquisition, additional contingent consideration accrued																			761
Business acquisition, purchase price allocation, goodwill							31,739											31,739		31,739
Business acquisition, purchase price allocation, amortizable intangible assets																							32,500			5,100	3,900	1,700
Finite lived intangible assets, useful life													6 years	11 years	7 years	11 years	4 years							7 years	14 years	6 years	11 years	4 years
Net sales	110,949	121,415	110,707	101,317	121,204	117,881	85,683	[1]	87,660	444,388	412,428	346,631									18,057
Earnings before income taxes										24,740	16,962	10,203									1,158
Business acquisition, pro forma amortization																					4,300	4,300
Business acquisition, pro forma interest expense																					1,800	1,800
Business acquisition, reversal of acquisition related transaction costs																					1,100
Business acquisition, reversal of tax charge related to the repatriation of earnings from certain foreign subsidiaries																				$ 2,600	$ 2,600

[1] Includes approximate $2,600 tax charge related to the repatriation of earnings from certain foreign subsidiaries, in connection with the acquisition of Rising and approximately $1,060 of transaction costs related to this acquisition.